SecBot SecBot
144 ·Filed Apr 20, 2026

DYN

Dyne Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed7mo ago SEC0001628280-26-026021
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

Monitor for a subsequent Form 4 or updated Form 144 to confirm whether the sale was executed. Given the small share quantity and institutional seller, this is a low-impact event unlikely to move the stock materially.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$19.21
T+0 close · Apr 20, 2026 · via day close
Latest settled
+18.27%
T+60 · $22.72
Vs SPY
+11.37%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 21 $19.21entry
  2. T+1 · 7mo ago +2.39%α +1.38% · $19.67
  3. T+5 · 7mo ago −5.47%α −6.55% · $18.16
  4. T+20 · 6mo ago −13.90%α −18.81% · $16.54
  5. T+60 · 4mo ago +18.27%α +11.37% · $22.72
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Atlas Venture Associates XI, L.P., a shareholder of Dyne Therapeutics, filed a Form 144 notifying intent to sell up to 1,401 shares of common stock. The filing is a routine notice of potential sale and does not confirm the transaction has occurred.

Key Facts

  • Reporting entity: Atlas Venture Associates XI, L.P.
  • Subject company: Dyne Therapeutics, Inc. (DYN)
  • Security type: Common stock
  • Number of shares proposed for sale: 1,401
  • Filing date: April 20, 2026
  • Method of sale: Not specified
  • Shares acquired via private placement on April 26, 2019

Financial Impact

Approximately $285,944 (based on 1,401 shares at ~$204/share, derived from $3.4B market cap and ~16.5M shares outstanding)

insider ownershippotential dilution

Risk Factors

  • Potential perception of negative sentiment if multiple insiders file near-simultaneous 144s
  • Execution of sale could contribute to near-term supply pressure, though minimal given size

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001628280-26-026021
Document: 0001628280-26-026021-index.html0001628280-26-026021
Document: 0001628280-26-026021.txt0001628280-26-026021

Track record

54 reports on DYN

Performance horizon

12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
  7. Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
  8. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
  9. Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
  10. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
Showing 10 of 54

US Market Status

Market Closed · Opens in 9h 28m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 20, 2026